This Program Project proposes a fundamental examination of the economic underpinnings of Medicare Part D and its consequences. Part D represents one of the most important reforms to the US Medicare system in its history, and a policy experiment with weighty consequences. We have assembled a team of researchers from several institutions with decades of experience studying the economics of consumer choice, the economics of aging, insurance design, pharmaceutical innovation, and health policy. Centered at RAND, administrative and data cores will promote close collaboration across the research teams, as well as links with CMS, NIA, and the external research community. The data core brings to bear a unique and lengthy list of datasets that permit study of many economic aspects of Part D, and provide opportunities for cross-validation of results. The five projects study Part D from an array of perspectives: beneficiaries;insurers;drug manufacturers;policy;and elderly households. The research projects complement each other in valuable ways, and they are supported by two Cores designed to ensure synergistic effort. Questions about demand for drugs, plan choice, and benefit design will be addressed through both reduced-form and structural analysis, and with a variety of administrative and survey data sets. Basic questions such as whether consumers behave rationally, and the value of Part D, will be addressed. The Administrative Core will support this effort by bringing together a Steering Committee of all project teams and convening annual summer workshops. It will also host two research conferences on Part D. In addition, a pilot program will develop innovative cross-cutting research. The administrative core will also support the development of Part D research in the external research community through visiting scholars, two annual research conferences, public use data files, and postdoctoral positions. In sum, this program project will provide an integrated economic evaluation of the welfare effects of Part D, and promote Medicare-related research of policy and scientific interest.

Public Health Relevance

Medicare Part D represents a large social experiment, and there is much we can learn from both a scientific and policy perspective. This POI will provide a comprehensive examination of the economic underpinnings of Medicare Part D and its welfare consequences using an array of methods and data sets.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG033559-03
Application #
8531805
Study Section
Special Emphasis Panel (ZAG1-ZIJ-1 (O4))
Program Officer
Baker, Colin S
Project Start
2011-09-15
Project End
2016-07-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
3
Fiscal Year
2013
Total Cost
$561,903
Indirect Cost
$219,453
Name
University of Southern California
Department
None
Type
Other Domestic Higher Education
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Jena, Anupam B; Goldman, Dana; Karaca-Mandic, Pinar (2016) Hospital Prescribing of Opioids to Medicare Beneficiaries. JAMA Intern Med 176:990-7
Lakdawalla, Darius; Shafrin, Jason; Lucarelli, Claudio et al. (2015) Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains. Health Aff (Millwood) 34:555-61
Lakdawalla, Darius N; Chou, Jacquelyn W; Linthicum, Mark T et al. (2015) Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer. JAMA Oncol 1:196-202
Lakdawalla, Darius; Yin, Wesley (2015) Insurers' Negotiating Leverage and the External Effects of Medicare Part D. Rev Econ Stat 97:314-331
Jena, Anupam B; Prasad, Vinay; Goldman, Dana P et al. (2015) Mortality and treatment patterns among patients hospitalized with acute cardiovascular conditions during dates of national cardiology meetings. JAMA Intern Med 175:237-44
Gaudette, Étienne; Goldman, Dana P; Messali, Andrew et al. (2015) Do Statins Reduce the Health and Health Care Costs of Obesity? Pharmacoeconomics 33:723-34
Jena, Anupam B; Ho, Oliver; Goldman, Dana P et al. (2015) The Impact of the US Food and Drug Administration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers Among Individuals With Asthma. JAMA Intern Med 175:1171-9
Romley, John A; Gong, Cynthia; Jena, Anupam B et al. (2015) Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis. BMJ 351:h6223
Vanderpuye-Orgle, Jacqueline; Zhao, Yang; Lu, Jackie et al. (2015) Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol 72:961-7.e5
Romley, John A; Goldman, Dana P; Sood, Neeraj (2015) US hospitals experienced substantial productivity growth during 2002-11. Health Aff (Millwood) 34:511-8

Showing the most recent 10 out of 22 publications